Close Menu

NEW YORK (GenomeWeb) – Vela Diagnostics said on Friday that the Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.

The Sentosa SX101 is a multi-purpose liquid handling platform that can process 21 separate sample types. It features open channel capabilities for automated sample extraction, PCR setup, next-generation sequencing library preparation, and Sanger sequencing cleanup. The platform is validated for use with Vela's automated and integrated PCR and NGS workflow.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.